Solid Tumor Targeting CAR-T Development Service with Dual ON/OFF Switch

Current CAR-T therapies for solid tumors face significant challenges, including on-target off-tumor toxicity, uncontrolled T cell activation, and limited persistence in the immunosuppressive tumor microenvironment. Creative Biolabs' Solid Tumor Targeting CAR-T Development Service with Dual ON/OFF Switch addresses these hurdles by integrating a clinically proven, drug-regulated remote-control system into CAR-T design. We engineer universal CAR architectures combined with bifunctional adapter molecules, enabling precise and reversible tuning of T cell activity using two orally available, clinically approved small molecules. Our approach offers enhanced safety through dose-dependent activation and rapid deactivation, while also improving T cell persistence by mitigating exhaustion.

Introduction

A dual-gated CAR-T system, termed VIPER CAR, is engineered with a viral protease domain that enables precise spatiotemporal control of T cell activity using NS3 protease inhibitors. In CAR-T immunotherapy, this reversible, dual-switch molecular design is critical. It not only offers an innovative strategy to overcome key challenges such as on-target/off-tumor toxicity, antigen escape, and T cell exhaustion in solid tumors, but also significantly enhances treatment safety and controllability through real-time ON/OFF switching capability.

Fig.1 Engineering next-generation CARs with precision ON/OFF control.

Solid Tumor Targeting CAR-T Development Service with Dual ON/OFF Switch at Creative Biolabs

Creative Biolabs' Solid Tumor Targeting CAR-T Development Service with Dual ON/OFF Switch introduces a drug-controlled molecular mechanism, offering a novel solution to balance safety and efficacy in solid tumor treatment. Our platform enables real-time mitigation of severe adverse effects while utilizing reversible T cell "resting" phases to counteract exhaustion, thereby addressing the dual challenges of toxicity and persistence. We are committed to delivering advanced CAR-T products that integrate superior safety, sustained potency, and sophisticated targeting logic.

What We Can Offer

We have intelligently integrated locally activatable or remotely controllable ON switches with reversibly inhibitory or permanently eliminable OFF switches, establishing a dynamic control system that combines precise activation with an emergency brake function.

Our Service Process

Required Starting Materials:

• Target Antigens: Precise details on 2-3 target surface markers specific to the solid tumor.
• CAR Construct Backbone: Any preferred signaling domains or antibody binders to integrate into the switch system.

Key steps:

Final Deliverables:

• High-Performance CAR-T Line.
• Comprehensive Functional Data Package: Includes ON/OFF kinetics, dose-response curves, specificity assays, and multi-antigen targeting efficacy reports.

Key Advantages

• Precision Synthetic Circuit Design: Custom design and synthesis of drug-gated CAR circuits optimized for specific solid tumor targets and co-stimulatory domains.
• Immediate-Onset OFF-Switches: Implementation of rapid, reversible OFF-switches for instantaneous toxicity control and CRS mitigation.
• Tunable ON-Switches for Persistence: Integration of drug-inducible ON-switches to strategically modulate T cell activity, prevent exhaustion, and maximize long-term anti-tumor persistence.
• Fully Customized Modality Selection: We offer fully tailored synthetic biology solutions, allowing you to select the precise switch modality and accompanying control drug, meticulously matched to your unique clinical program requirements.

FAQ

Why Choose Us?

As your partner in solid tumor CAR-T development, we offer unparalleled precision. Our orthogonal ON/OFF switches enable independent, multi-drug control for enhanced safety and to prevent antigen escape. Our dual ON/OFF switches armed CAR-T ensure superior kinetics and facilitate rapid development. Choose us for a de-risked path to a potent, controllable, and safer therapeutic.

Customer Reviews

"We needed a truly rapid 'OFF' switch. The speed of the lenalidomide-induced degradation CAR developed by Creative Biolabs was far superior to earlier systems, transitioning our T cells to a functionally inactive state within 24 hours. This level of precision modulation is unparalleled." L*aura W.

"The dose-titratable and rapid reversibility using Creative Biolabs' small-molecule signaling inhibition platform has been a game-changer. It allowed us to move from fatal toxicity to manageable CRS in our mouse models. We gained confidence in the safety profile immediately." G*eorge S.

"Using the orthogonal, multiplexed CAR circuits in our project significantly improved our ability to target heterogeneous solid tumors. We finally achieved simultaneous, independent control, which is the advanced logic needed to enhance persistence." A*na B.

How to Contact Us?

Our Dual ON/OFF Switch platform is engineered to directly address the critical barriers in solid tumor CAR-T therapy: on-target/off-tumor toxicity and antigen escape. By integrating orthogonal control mechanisms, we deliver enhanced therapeutic precision, improved safety profiles, and accelerated clinical translation. Partner with us to transform your solid tumor programs with tailored, controllable cell therapies.